REVIVA PHARMACEUTICALS HOLDINGS, INC.

Tenzing Acquisition Corp, trading under the ticker TZAC, was a blank-check company that completed its initial public offering in 2019 with a focus on the healthcare and biopharmaceutical sector. Sponsored by Tenzing Capital, the SPAC announced a business combination with Reviva Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with the combined entity filing under the name Reviva Pharmaceuticals Holdings, Inc. The October 2020 10-Q filing reflects the company's status as the merger with Reviva moved through regulatory and shareholder approval processes. The transaction ultimately positioned the combined company within the CNS therapeutics space. Sign up for full data, filings, and deal timelines on SpacDesk.